Unmasking molecular profiles of bladder cancer
- PMID: 29520382
- PMCID: PMC5840121
- DOI: 10.4111/icu.2018.59.2.72
Unmasking molecular profiles of bladder cancer
Abstract
Precision medicine is designed to tailor treatments for individual patients by factoring in each person's specific biology and mechanism of disease. This paradigm shifted from a "one size fits all" approach to "personalized and precision care" requires multiple layers of molecular profiling of biomarkers for accurate diagnosis and prediction of treatment responses. Intensive studies are also being performed to understand the complex and dynamic molecular profiles of bladder cancer. These efforts involve looking bladder cancer mechanism at the multiple levels of the genome, epigenome, transcriptome, proteome, lipidome, metabolome etc. The aim of this short review is to outline the current technologies being used to investigate molecular profiles and discuss biomarker candidates that have been investigated as possible diagnostic and prognostic indicators of bladder cancer.
Keywords: Biomarkers; Liquid biopsy; Precision medicine; Urinary bladder neoplasms.
Conflict of interest statement
CONFLICTS OF INTEREST: The authors have nothing to disclose.
Figures
Similar articles
-
Biomarkers for precision medicine in bladder cancer.Int J Clin Oncol. 2017 Apr;22(2):207-213. doi: 10.1007/s10147-016-1068-8. Epub 2016 Nov 29. Int J Clin Oncol. 2017. PMID: 27896485 Review.
-
Multiplex assay for multiomics advances in personalized-precision medicine.J Immunoassay Immunochem. 2019;40(1):3-25. doi: 10.1080/15321819.2018.1562940. Epub 2019 Jan 11. J Immunoassay Immunochem. 2019. PMID: 30632882 Review.
-
Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.Proteomics Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700074. Epub 2017 Oct 25. Proteomics Clin Appl. 2018. PMID: 28980455 Review.
-
Precision medicine and bladder cancer heterogeneity.Bull Cancer. 2018 Oct;105(10):925-931. doi: 10.1016/j.bulcan.2018.07.015. Epub 2018 Sep 20. Bull Cancer. 2018. PMID: 30243478 Review.
-
An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer.BMC Urol. 2015 Jul 1;15:59. doi: 10.1186/s12894-015-0056-z. BMC Urol. 2015. PMID: 26126604 Free PMC article.
Cited by
-
Urinary Markers in Bladder Cancer: An Update.Front Oncol. 2018 Sep 7;8:362. doi: 10.3389/fonc.2018.00362. eCollection 2018. Front Oncol. 2018. PMID: 30245975 Free PMC article. Review.
-
ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A.Cell Death Dis. 2021 Jul 1;12(7):661. doi: 10.1038/s41419-021-03947-7. Cell Death Dis. 2021. PMID: 34210956 Free PMC article.
-
Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients.Sci Rep. 2018 Dec 6;8(1):17693. doi: 10.1038/s41598-018-35637-4. Sci Rep. 2018. PMID: 30523270 Free PMC article.
-
A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy.Int J Mol Sci. 2021 Feb 1;22(3):1450. doi: 10.3390/ijms22031450. Int J Mol Sci. 2021. PMID: 33535616 Free PMC article.
-
CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD.Biomed Res Int. 2020 Feb 20;2020:7638975. doi: 10.1155/2020/7638975. eCollection 2020. Biomed Res Int. 2020. PMID: 32149134 Free PMC article.
References
-
- Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res. 2010;8:1175–1187. - PubMed
-
- Johnson DC, Greene PS, Nielsen ME. Surgical advances in bladder cancer: at what cost? Urol Clin North Am. 2015;42:235–252. ix. - PubMed
-
- Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–241. - PubMed
-
- Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–249. - PubMed
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical